FORWARD.one’s Post

Amazing news for our portfolio company, IoTeX. Incredible to see their team grows as they secured a funding round and will inevitably have continued success on the horizon! The information provided in this post is for educational and informational purposes only and is not intended to be investment advice or a recommendation. Struck has no obligation to update, modify, or amend the contents of this blog post nor to notify readers in the event that any information, opinion, forecast or estimate changes or subsequently becomes inaccurate or outdated. In addition, certain information contained herein has been obtained from third party sources and has not been independently verified by Struck. The company featured in this blog post is for illustrative purposes only, has been selected in order to provide an example of the types of investments made by Struck that fit the theme of this blog post and is not representative of all Struck portfolio companies. Struck Capital Management LLC is registered with the United States Securities and Exchange Commission (“SEC”) as a Registered Investment Adviser (“RIA”). Nothing in this communication should be considered a specific recommendation to buy, sell, or hold a particular security or investment. Past performance of an investment does not guarantee future results. All investments carry risk, including loss of principal.

While the Triangle region is not home to some of the larger VC's in the life science space, in Q3 we saw a rebound in VC funding. Funding for early-stage companies increased 48% quarter-over-quarter – the largest amount in the past five quarters. This is something we are seeing on a national scale. #vcfunding #lifesciences #RTP https://lnkd.in/ekKmCXDB

In the fast-paced world of biotechnology, startups are constantly pushing the boundaries of what's possible in healthcare. But bringing groundbreaking ideas to fruition requires more than just brilliant minds – it takes the financial backing and strategic guidance of experienced venture capital firms. Our team has conducted research to identify the top VCs that are making significant investments in the biotech space. From early-stage funding to long-term partnerships, these firms are providing the resources and expertise needed to help startups thrive. Check it out: https://lnkd.in/gpEGH7Pn New Enterprise Associates (NEA) Third Rock Ventures OrbiMed Versant Ventures New Leaf Venture Partners Flagship Ventures Kleiner Perkins Canaan Third Security, LLC InterWest Partners Alta Partners EW Healthcare Partners Novo Holdings Casdin Capital, LLC #biotechstartups #venturecapital #healthcareinnovation #biotechnology #investors #startupfunding

IoTeX has secured a $50 Million investment to accelerate DePIN ecosystem growth and adoption. Backed by SNZ Capital, Foresight Ventures, Borderless Capital, Amber Group, FutureMoney Group, Metrics Ventures, Escape Velocity (EV3), Waterdrip Capital , Summer Capital, and Others. The $50 million investment will go toward accelerating #DePIN growth and adoption through an investment in long-term staked $IOTX, the DePIN token that governs and fuels the #IoTeX DePIN ecosystem as well as investment in the DePIN projects building on IoTeX with the IoTeX Foundation and the DePINsurf accelerator fund. Jing Sun, Co-Founder and Head of Investment of IoTeX, said, "The richness of the ever-growing DePIN ecosystem presents an exciting opportunity for startups to innovate and bring verified, real-world data on-chain. As a modular infrastructure, IoTeX fast-forwards the growth of projects building with us. The investment from these top VCs will act as a catalyst for this industry sector, spurring the growth of more projects in the IoTeX ecosystem and DePIN as a whole." Read more: https://lnkd.in/eDUudGCj

It’s encouraging to read the news about the uptick in #VC activity in #lifesciences.   But it’s not just the big VC firms raising $$. Many of the smaller VC firms are also raising millions of dollars to support dozens of early stage #biotech companies doing exciting things!   These are leading indicators of good things to come in 2025!   #executivesearch

In the latest edition of AOS, our partners unveil the genesis of our VC fund and the vision moving forward - with significant announcements to come in the coming weeks and months. Read below 👇 #venturecapital #science #university #research

Biotech is back! Venture Capital-led funding rounds greater than $100 million in biotech startups is nearing 2021 levels, according to The Wall Street Journal. RTW Investments, LP Partner and Chief Business Officer Stephanie A. Sirota recently spoke with WSJ’s Brian Gormley to discuss this trend and the state of venture investing in biotech. Read the full article here (subscription required): https://lnkd.in/evesJWUv #Biotech #Investing #VentureCapital

Nanotech Capital Raises in the U.S. - September 16th-30th, 2024 Several interesting transactions closed in the Nanotech sector this week. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me. Later Stage VC 1. Nomic, a protein profiling platform, raised $42 million venture funding from Avant Bio, Real Ventures, Lux Capital, SR One Capital Management, Amplitude Ventures, and others. 2. Utility Global, a clean energy technology company, raised $53 million venture funding in a deal led by Ontario Power Generation, with participation from Aramco Ventures, Saint-Gobain NOVA, ArcelorMittal, and Ara Partners. 3. Peptinovo Biopharma, a biotech startup, raised an additional $1.32 million venture funding from MichBio, Biosciences Research and Commercialization Center, and Keiretsu Forum, putting the company's pre-money valuation at $19 million. 4. MetOx International, a power delivery technology company, raised $25 million venture funding led by New System Ventures and Centaurus Capital LP. 5. Revolution Space, a nanotech firm, raised $5.7 million of venture funding from undisclosed investors. The funds will support the company's ongoing projects in space technology. #castleplacement #capitalraising #privateequity #venturecapital #nanotech #investment

In 2021, North American and European firms raised an impressive $29.2 billion across 128 life sciences-focused venture funds, according to PitchBook Data. However, life sciences venture fundraising has experienced a decline since then. In 2022, venture firms secured $16.3 billion across 79 funds, and in 2023, the total was $15.8 billion from 46 funds, per PitchBook's data. This trend has continued into 2024, with only $3.4 billion raised for 11 life sciences venture funds as of May 21, according to PitchBook. Many firms are still looking for the big investment success that propels their next fundraising, said Kazi Y. Helal, PhD, a senior analyst with PitchBook. Read more in The Wall Street Journal 👇

CVC funds and VC investments in Poland have decreased by 50% in 2023 compared to 2021, with only three new funds launched: AVIVO Capital, LSA Ventures and Radix Ventures. The global slowdown in the technology sector and the completion of investment cycles contributed to this decline. AIN.Capital shares key points of Inovo.vc's summary. #report #Poland #funds